JP2006518756A5 - - Google Patents

Download PDF

Info

Publication number
JP2006518756A5
JP2006518756A5 JP2006503797A JP2006503797A JP2006518756A5 JP 2006518756 A5 JP2006518756 A5 JP 2006518756A5 JP 2006503797 A JP2006503797 A JP 2006503797A JP 2006503797 A JP2006503797 A JP 2006503797A JP 2006518756 A5 JP2006518756 A5 JP 2006518756A5
Authority
JP
Japan
Prior art keywords
alkyl
group
heteroaryl
aryl
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006503797A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006518756A (ja
Filing date
Publication date
Priority claimed from US10/780,917 external-priority patent/US20040209937A1/en
Application filed filed Critical
Publication of JP2006518756A publication Critical patent/JP2006518756A/ja
Publication of JP2006518756A5 publication Critical patent/JP2006518756A5/ja
Withdrawn legal-status Critical Current

Links

JP2006503797A 2003-02-24 2004-02-23 インドリノン化合物による過度の骨溶解の治療 Withdrawn JP2006518756A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44886103P 2003-02-24 2003-02-24
US10/780,917 US20040209937A1 (en) 2003-02-24 2004-02-19 Treatment of excessive osteolysis with indolinone compounds
PCT/US2004/005283 WO2004075775A2 (en) 2003-02-24 2004-02-23 Treatment of excessive osteolyisis with indolinone compounds

Publications (2)

Publication Number Publication Date
JP2006518756A JP2006518756A (ja) 2006-08-17
JP2006518756A5 true JP2006518756A5 (cg-RX-API-DMAC7.html) 2007-02-15

Family

ID=32930497

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006503797A Withdrawn JP2006518756A (ja) 2003-02-24 2004-02-23 インドリノン化合物による過度の骨溶解の治療

Country Status (11)

Country Link
US (1) US20040209937A1 (cg-RX-API-DMAC7.html)
EP (1) EP1599207A2 (cg-RX-API-DMAC7.html)
JP (1) JP2006518756A (cg-RX-API-DMAC7.html)
KR (1) KR20050113612A (cg-RX-API-DMAC7.html)
AU (1) AU2004216188A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0407793A (cg-RX-API-DMAC7.html)
CA (1) CA2516786A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05008961A (cg-RX-API-DMAC7.html)
NZ (1) NZ541825A (cg-RX-API-DMAC7.html)
PL (1) PL378762A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004075775A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006245421A1 (en) * 2005-05-12 2006-11-16 Pfizer Inc. Anticancer combination therapy using sunitinib malate
RU2399619C2 (ru) * 2005-09-19 2010-09-20 Пфайзер Продактс Инк. Твердые солевые формы замещенного пирролом 2-индолинона
CN101379400A (zh) * 2005-12-22 2009-03-04 诺华有限公司 可溶性人m-csf受体及其应用
CN101367801B (zh) * 2007-08-15 2011-01-12 上海恒瑞医药有限公司 吡咯并六元n杂环羟基吗啡啉类衍生物的制备方法及其在医药上的应用
EP2318364A2 (en) * 2008-07-02 2011-05-11 Generics [UK] Limited Preparation of 3-pyrrole substituted 2-indolinone derivatives
JP2011527330A (ja) * 2008-07-10 2011-10-27 ジェネリクス・(ユーケー)・リミテッド スニチニブリンゴ酸塩の結晶形の調製方法
CN102239163A (zh) * 2008-07-24 2011-11-09 特瓦制药工业有限公司 通过乙酸舒尼替尼和它们的多晶型物制备苹果酸舒尼替尼的方法
CA2731605A1 (en) * 2008-07-24 2010-01-28 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
EP2181991A1 (en) * 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
US10898211B2 (en) 2015-01-14 2021-01-26 Crossroads Extremity Systems, Llc Opening and closing wedge osteotomy guide and method
US10292713B2 (en) 2015-01-28 2019-05-21 First Ray, LLC Freeform tri-planar osteotomy guide and method
US10376268B2 (en) 2015-02-19 2019-08-13 First Ray, LLC Indexed tri-planar osteotomy guide and method
CN109311811B (zh) * 2016-06-09 2022-09-09 有机合成药品工业株式会社 4-(哌啶-4-基)吗啉的制备方法
WO2021021640A1 (en) 2019-07-26 2021-02-04 Crossroads Extremity Systems, Llc Bone repositioning guide system and procedure
US11304735B2 (en) 2020-02-19 2022-04-19 Crossroads Extremity Systems, Llc Systems and methods for Lapidus repair of bunions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020751B1 (hr) * 2000-02-15 2011-01-31 Sugen Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
JP2005508953A (ja) * 2001-10-10 2005-04-07 スージェン・インコーポレーテッド キナーゼ阻害剤としての3−[4−(置換ヘテロサイクリル)−ピロール−2−イルメチリデン]−2−インドリノン誘導体
AU2003233576A1 (en) * 2002-05-17 2003-12-02 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals

Similar Documents

Publication Publication Date Title
JP7380507B2 (ja) Sting作動化合物
RU2483061C2 (ru) Тетрагидропиранохроменовые ингибиторы гамма-секретазы
JP2013528602A5 (cg-RX-API-DMAC7.html)
JP2009534386A5 (cg-RX-API-DMAC7.html)
JP2017531041A5 (cg-RX-API-DMAC7.html)
JP2006508981A5 (cg-RX-API-DMAC7.html)
JP2008535903A5 (cg-RX-API-DMAC7.html)
JP2013516393A5 (cg-RX-API-DMAC7.html)
JP2013503139A5 (cg-RX-API-DMAC7.html)
JP2013544276A5 (cg-RX-API-DMAC7.html)
JP2005500311A5 (cg-RX-API-DMAC7.html)
JP2009504764A5 (cg-RX-API-DMAC7.html)
JP2005112864A5 (cg-RX-API-DMAC7.html)
JP2010511721A5 (cg-RX-API-DMAC7.html)
MY140528A (en) Spiroketal derivatives and their use as therapeutic agents for diabetes
JP2011219498A5 (cg-RX-API-DMAC7.html)
MXPA05010712A (es) Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias.
AU2006272652B2 (en) 1,2,3-triazoles inhibitors of tubulin polymerization for the treatment of proliferative disorders
EP2457918A3 (en) Crystalline solvates and complexes of (1s)-1,5-anhydro-1-c-(3-((phenyl) methyl) phenyl)-d-glucitol derivatives with amino acids as SGLT2 inhibitors for the treatment of diabetes
TW200833663A (en) Therapeutic agents
PE20090151A1 (es) Derivados de pirimidinona y metodos para su uso
JP2006524222A5 (cg-RX-API-DMAC7.html)
JP2009535358A5 (cg-RX-API-DMAC7.html)
JP2009519243A5 (cg-RX-API-DMAC7.html)
JP2006505543A5 (cg-RX-API-DMAC7.html)